相似文献
1
Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges.
Virulence. 2016;7(2):201-8. doi: 10.1080/21505594.2015.1085151. Epub 2015 Aug 25.
2
Hepatitis C transmission and treatment as prevention - The role of the injecting network.
Int J Drug Policy. 2015 Oct;26(10):958-62. doi: 10.1016/j.drugpo.2015.05.006. Epub 2015 May 21.
3
Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.
Int J Drug Policy. 2015 Oct;26(10):976-83. doi: 10.1016/j.drugpo.2015.05.003. Epub 2015 May 21.
4
Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
Addiction. 2018 Nov;113(11):2118-2131. doi: 10.1111/add.14267. Epub 2018 Jul 10.
5
Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium.
Acta Gastroenterol Belg. 2016 Apr-Jun;79(2):227-32.
6
Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
Vaccine. 2019 May 1;37(19):2608-2616. doi: 10.1016/j.vaccine.2019.02.081. Epub 2019 Apr 5.
7
Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review.
J Viral Hepat. 2015 Mar;22(3):213-29. doi: 10.1111/jvh.12337. Epub 2014 Oct 1.
8
Modelling the prevalence of HCV amongst people who inject drugs: an investigation into the risks associated with injecting paraphernalia sharing.
Drug Alcohol Depend. 2013 Nov 1;133(1):172-9. doi: 10.1016/j.drugalcdep.2013.05.014. Epub 2013 Jun 20.
9
Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence.
Curr Opin Infect Dis. 2015 Dec;28(6):576-82. doi: 10.1097/QCO.0000000000000216.
10
Drug network identification predicts injecting risk behavior among people who inject drugs on hepatitis C virus treatment in Tayside, Scotland.
Behav Med. 2024 Apr-Jun;50(2):130-140. doi: 10.1080/08964289.2022.2142501. Epub 2022 Nov 21.
引用本文的文献
1
Evaluating Montréal's harm reduction interventions for people who inject drugs: protocol for observational study and cost-effectiveness analysis.
BMJ Open. 2021 Oct 26;11(10):e053191. doi: 10.1136/bmjopen-2021-053191.
2
Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: A model-based analysis.
PLoS Med. 2020 Oct 13;17(10):e1003239. doi: 10.1371/journal.pmed.1003239. eCollection 2020 Oct.
3
A review of network simulation models of hepatitis C virus and HIV among people who inject drugs.
Int J Drug Policy. 2021 Feb;88:102580. doi: 10.1016/j.drugpo.2019.10.006. Epub 2019 Nov 15.
4
Injection drug network characteristics as a predictor of injection behaviour.
Epidemiol Infect. 2019 Jan;147:e173. doi: 10.1017/S095026881900061X.
5
The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study.
Lancet Gastroenterol Hepatol. 2019 Jun;4(6):435-444. doi: 10.1016/S2468-1253(19)30085-8. Epub 2019 Apr 10.
6
Structural Sensitivity in HIV Modeling: A Case Study of Vaccination.
Infect Dis Model. 2017 Nov;2(4):399-411. doi: 10.1016/j.idm.2017.08.002. Epub 2017 Nov 11.
7
Eliminating hepatitis C virus as a public health threat among HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour.
J Int AIDS Soc. 2018 Jan;21(1). doi: 10.1002/jia2.25059.
8
Editorial: Mathematical modeling of infectious disease dynamics.
Virulence. 2016;7(2):119-20. doi: 10.1080/21505594.2016.1150402.
本文引用的文献
1
The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments.
BMC Med. 2015 Aug 20;13:198. doi: 10.1186/s12916-015-0440-2.
2
Nine challenges for deterministic epidemic models.
Epidemics. 2015 Mar;10:49-53. doi: 10.1016/j.epidem.2014.09.006. Epub 2014 Sep 27.
3
Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data.
J R Soc Interface. 2015 Mar 6;12(104):20141197. doi: 10.1098/rsif.2014.1197.
4
Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first?
Addiction. 2015 Jun;110(6):975-83. doi: 10.1111/add.12842. Epub 2015 Feb 8.
5
A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing.
J Hepatol. 2014 Nov;61(1 Suppl):S34-44. doi: 10.1016/j.jhep.2014.09.009. Epub 2014 Nov 3.
6
Benefits of hepatitis C virus treatment: a balance of preventing onward transmission and re-infection.
Math Biosci. 2014 Dec;258:11-8. doi: 10.1016/j.mbs.2014.09.006. Epub 2014 Sep 19.
7
High-frequency drug purity and price series as tools for explaining drug trends and harms in Victoria, Australia.
Addiction. 2015 Jan;110(1):120-8. doi: 10.1111/add.12740. Epub 2014 Oct 23.
8
The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs.
Hepatology. 2014 Dec;60(6):1861-70. doi: 10.1002/hep.27403. Epub 2014 Oct 24.
9
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.
J Viral Hepat. 2014 May;21 Suppl 1:34-59. doi: 10.1111/jvh.12248.
10
Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data.
J Viral Hepat. 2014 Jan;21(1):25-32. doi: 10.1111/jvh.12117. Epub 2013 May 28.
Zotero 插件